IRIS
RIZZOLI, Vittorio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.644
AS - Asia 6.588
EU - Europa 4.275
SA - Sud America 772
AF - Africa 304
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 2
Totale 18.602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.428
SG - Singapore 2.368
CN - Cina 2.008
VN - Vietnam 963
IE - Irlanda 763
FI - Finlandia 741
SE - Svezia 739
BR - Brasile 598
UA - Ucraina 564
DE - Germania 550
HK - Hong Kong 437
TR - Turchia 271
FR - Francia 200
IT - Italia 200
ZA - Sudafrica 200
NL - Olanda 183
BD - Bangladesh 174
CA - Canada 149
GB - Regno Unito 114
IN - India 90
AR - Argentina 69
RU - Federazione Russa 51
CI - Costa d'Avorio 42
MX - Messico 39
EC - Ecuador 38
IQ - Iraq 33
JP - Giappone 32
BE - Belgio 31
RO - Romania 25
PL - Polonia 24
PH - Filippine 23
ID - Indonesia 22
IR - Iran 22
ES - Italia 18
PK - Pakistan 18
CO - Colombia 17
TH - Thailandia 17
TW - Taiwan 17
MA - Marocco 16
CZ - Repubblica Ceca 15
EU - Europa 15
UZ - Uzbekistan 14
LT - Lituania 13
UY - Uruguay 12
SA - Arabia Saudita 10
AT - Austria 9
CL - Cile 9
PY - Paraguay 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
KR - Corea 8
PE - Perù 8
EG - Egitto 7
KE - Kenya 7
LV - Lettonia 7
DO - Repubblica Dominicana 6
MY - Malesia 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
CR - Costa Rica 5
DZ - Algeria 5
ET - Etiopia 5
JM - Giamaica 5
KZ - Kazakistan 5
NP - Nepal 5
HN - Honduras 4
IL - Israele 4
NG - Nigeria 4
SK - Slovacchia (Repubblica Slovacca) 4
LK - Sri Lanka 3
OM - Oman 3
SN - Senegal 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
LB - Libano 2
LU - Lussemburgo 2
MD - Moldavia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AU - Australia 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CM - Camerun 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
Totale 18.587
Salva come PNG Salva come JPEG
Città #
Singapore 1.155
Dublin 763
Ashburn 713
Chandler 712
Jacksonville 654
San Jose 597
Beijing 453
Hong Kong 403
Santa Clara 381
Ho Chi Minh City 279
Dearborn 253
Nanjing 238
Izmir 227
Boardman 226
Dallas 221
Hanoi 211
Johannesburg 191
San Mateo 186
Princeton 160
Los Angeles 154
Ann Arbor 141
Lauterbourg 141
Toronto 108
Shanghai 103
New York 98
Wilmington 98
Shenyang 88
Nanchang 82
Helsinki 76
Kunming 74
Hefei 73
Munich 70
Hebei 65
Düsseldorf 63
Jinan 63
Buffalo 61
São Paulo 56
Parma 50
Des Moines 49
Da Nang 47
Haiphong 45
Abidjan 42
Woodbridge 40
Changsha 39
Marseille 38
Guangzhou 37
Tianjin 37
Jiaxing 35
Bremen 33
Moscow 33
Brussels 31
Columbus 31
Pune 30
Seattle 29
Kocaeli 26
Leawood 25
Stockholm 24
Turku 24
Zhengzhou 24
Tokyo 23
Frankfurt am Main 22
Grafing 22
Warsaw 22
Houston 21
Hải Dương 21
Atlanta 20
Brooklyn 20
Hangzhou 20
Montreal 20
Augusta 19
Council Bluffs 19
Norwalk 19
San Francisco 18
London 17
Ningbo 16
Orem 16
Phoenix 16
Amsterdam 15
Focsani 15
Milan 15
Rio de Janeiro 15
Mestre 14
Boston 13
Lanzhou 13
Monmouth Junction 13
Nuremberg 13
Pittsburgh 13
Tashkent 13
Ardabil 12
Bologna 12
Chongqing 12
Denver 12
Fremont 12
Guayaquil 12
Haikou 12
Thái Nguyên 12
Biên Hòa 11
Chicago 11
Quito 11
Taizhou 11
Totale 11.049
Salva come PNG Salva come JPEG
Nome #
Diabetes impairs hematopoietic stem cell mobilization by altering niche function 253
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 227
Are the Myeloma bone microevironment cells tumoral or not? 224
The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment 205
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 195
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 184
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 183
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 183
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 178
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 177
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 175
Amifostine (WR-2721) selective protection against melphalan genotoxicity 174
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 172
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 171
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 168
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 167
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. 162
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 161
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 160
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 158
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 157
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 157
Angiopoietins expression by human myeloma cells 156
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 156
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 152
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 152
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 152
Angiogenic switch in multiple myeloma patients 151
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 150
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 148
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 148
Angiogenic properties of human myeloma cells: role of angiopoietin system 147
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 147
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 147
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 145
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 144
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 144
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 143
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 143
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 143
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 142
Bleomycin Genotoxicity and Amifostine (WR-2721) Cell Protection in Normal Leukocytes versus K562 Tumoral Cells 142
Do human myeloma cells directly produce basic FGF? 141
Alterations of microenvironment in multiple myeloma patients: Interactions between myeloma cells and osteoprogenitor cells 141
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 140
Angiopoietin-1 and myeloma-induced angiogenesis 138
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 136
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 135
A distintive nuclear morfology in three cases of acute myeloid leukaemia associated with loss HLA-DR expression and FTL3 internal tandem duplication 135
EPIRUBICIN PLUS G-CSF ELICITED PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IS SIGNIFICANTLY ENHANCED BY AMIFOSTINE 134
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 134
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 133
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 129
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. 129
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. 129
Expression and role of chemokine receptor CXCR3 in multiple myeloma 128
Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. 128
Angiogenic switch in multiple myeloma 126
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 125
Autotransplantation in acute leukemia. 125
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets 123
Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy 122
Arsenic trioxide in hematological malignancies: The new discovery of an ancient drug 121
DKK-1 and sFRP-3 expression by myeloma cell and bone marrow plasma levels in multiple myeloma and MGUS patients: Potential relationship with bone status. 121
RANKL is critically involved in the physiopathology of multiple myeloma 121
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 118
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 118
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 118
Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow. 118
Beta-catenin depended and independent effects induced by myeloma cells in human and murine osteoblasts and osteoblast progenitors. 117
Mossbauer analysis of bone marrow before and after purging with Asta-z 7557 117
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 116
Osteopontin is produced by human multiple myeloma cells 116
p29ING4 regulates the production of pro-angiogenic molecules by human myeloma cells in normoxic and hypoxic conditions being involved in myeloma-induced angiogenesis. 116
Effects of Mössbauer radiation on bone marrow cultures 113
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group 112
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 111
DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay 110
Impact of XIAP protein levels on the survival of myeloma cells 109
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens 109
Multiple myeloma patient with unusual extramedullary involvement 108
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 108
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 107
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 107
The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients. 105
HUMAN MYELOMA CELLS EXPRESS THE BONE REGULATING GENE RUNX2/CBFA1 AND PRODUCE OSTEOPONTIN THAT IT IS INVOLVED IN MYELOMA INDUCED ANGIOGENESIS 104
IL-7 is produced by myeloma cells in presence of IL-6 102
Human myeloma cells produce angiopoietin-1: potential relationship with myeloma-induced angiogenesis 101
Purging the bone marrow in non-Hodgkin's lymphomas. Is there any evidence of its value? 101
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 100
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 100
MYELOMA CELLS BLOCK RUNX2/CBFA1 ACTIVITY IN HUMAN BONE MARROW OSTEOBLAST PROGENITORS AND INHIBIT OSTEOBLAST FORMATION AND DIFFERENTIATION 99
Role of tumor necrosis factor-related activation-induced cytokine (TRANCE) in multiple myeloma 99
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 99
The proteasome inhibitor bortezomib stimulates the osteogenic differentiation of mesenchymal cells in vitro and may increase osteoblast formation in vivo in multiple myeloma patients. 99
Evaluation of amifostine (WR-271) cytoprotection against in vitro bleomycin-induced clastogenicity in human leukocytes by SCGE assay 98
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients 98
Expression of pro-angiogenetic factors by myeloma cells: role of the angiopoietin system 97
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 97
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients 97
Totale 13.681
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.313
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.313
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 0 0 0 0 0 0 29
2021/2022784 11 2 5 56 16 31 94 137 35 85 80 232
2022/20232.743 357 295 171 193 250 284 53 151 891 11 74 13
2023/2024866 40 105 21 16 75 196 82 89 22 41 69 110
2024/20252.899 52 178 198 202 313 284 47 93 419 283 242 588
2025/20266.649 576 589 763 665 1.006 402 688 208 904 472 240 136
Totale 18.698